Notice: This company has been marked as potentially delisted and may not be actively trading. Cerevel Therapeutics (CERE) News Today Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiationsJanuary 18, 2025 | markets.businessinsider.comAbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?January 16, 2025 | finance.yahoo.comAbbVie plans to 'commit less capital' towards psychiatric drugs, CEO saysJanuary 15, 2025 | msn.comAbbVie CEO says psychiatric drug space challenging, more cautious on investmentsJanuary 15, 2025 | msn.comBlueRock accelerates Parkinson’s disease therapy to Phase IIIJanuary 14, 2025 | msn.comCeres Power Applies for Block Listing on LSE to Boost GrowthJanuary 14, 2025 | tipranks.comAbbVie secures option to license Simcere's blood cancer drug candidateJanuary 13, 2025 | msn.comHealth Care Down on Defensive Bias -- Health Care RoundupJanuary 11, 2025 | marketwatch.comAbbVie sees $3.5B impairment charge related to emraclidineJanuary 11, 2025 | markets.businessinsider.comAbbVie to record $3.5B impairment charge for Cerevel drugJanuary 11, 2025 | msn.comAbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia DrugJanuary 10, 2025 | msn.comCompanies sold a record $8 trillion of bonds last year amid high demand and lower borrowing costsJanuary 3, 2025 | msn.comGlobal corporate borrowing climbs to record $8tn in 2024December 27, 2024 | ft.comTerragen Holdings Sees Shift as Ceres Capital ExitsDecember 18, 2024 | tipranks.comAbbVie Stock Volatile On $200M Deal To Buy Nimble Therapeutics: Retail Still BearishDecember 13, 2024 | msn.comHope for Parkinson’s disease symptoms is found in late-stage drug studyDecember 10, 2024 | msn.comIs AbbVie Stock Underperforming the Dow?December 9, 2024 | msn.comAbbVie's Tavapadon Hits Key Goals in Third Phase 3 Parkinson's Study -- UpdateDecember 9, 2024 | marketwatch.comAbbVie's Parkinson's disease drug improves patient mobility in late-stage studyDecember 9, 2024 | msn.comFrom Cobenfy to Emraclidine: the muscarinic path to safer antipsychoticsDecember 3, 2024 | finance.yahoo.comCeres Power Director Buys Shares, Boosting Green Energy FocusNovember 28, 2024 | tipranks.comAbbVie Tumbles After New Schizophrenia Drug Fails Two TrialsNovember 11, 2024 | finance.yahoo.comAbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock SurgesNovember 11, 2024 | benzinga.comAbbVie's closely watched schizophrenia drug fails two studies, shares slideNovember 11, 2024 | msn.comRapport Therapeutics adds new members to Board of DirectorsNovember 8, 2024 | markets.businessinsider.comAbbVie Inc (ABBV) Q3 2024 Earnings Call Highlights: Strong Growth in Ex-Humira Platform and ...November 1, 2024 | finance.yahoo.comAbbVie Inc. (NYSE:ABBV) Q3 2024 Earnings Call TranscriptNovember 1, 2024 | msn.comAbbVie (ABBV) Q3 2024 Earnings Call TranscriptOctober 30, 2024 | msn.comAbbVie to buy Alzheimer's therapy developer Aliada for US$1.4 billionOctober 28, 2024 | msn.comAbbVie lowers first-quarter guidance after closing acquisition ImmunoGenOctober 14, 2024 | msn.comMindfulness Meditation Similar to Antidepressant for Reducing Anxiety SymptomsOctober 11, 2024 | msn.comAbbVie: A Strong Investment Opportunity In Neurological And Oncology BreakthroughsOctober 3, 2024 | seekingalpha.comAbbVie's Emraclidine: M4 Agonist Might Become Best-In-Class In SchizophreniaOctober 3, 2024 | seekingalpha.comKailera Therapeutics nets $400 million as weight-loss drug market heats upOctober 2, 2024 | msn.comAbbVie Inc. (ABBV) Projects Mid-Single-Digit Sales Growth Over Next 3 YearsSeptember 30, 2024 | msn.comHalf Year 2024 Ceres Power Holdings PLC Earnings Presentation TranscriptSeptember 30, 2024 | gurufocus.com8 Best Inexpensive Stocks To Invest In NowSeptember 27, 2024 | insidermonkey.com15 Unhealthiest Countries in Latin AmericaSeptember 27, 2024 | msn.comBristol Myers Gets US Nod for First New Schizophrenia Drug Type in DecadesSeptember 27, 2024 | msn.comBristol Myers wins US FDA approval for new type of schizophrenia drugSeptember 27, 2024 | msn.comAbbVie’s $8.7bn Parkinson’s disease drug shines in Phase III trialSeptember 27, 2024 | finance.yahoo.comAbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early DiseaseSeptember 27, 2024 | benzinga.comCardurion Pharmaceuticals Appoints Ron Renaud to Board of DirectorsSeptember 26, 2024 | finance.yahoo.comAbbVie: Tavapadon Meets Key Endpoints in Phase 3 Parkinson's StudySeptember 26, 2024 | marketwatch.comBristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 YearsSeptember 20, 2024 | benzinga.comSchizophrenia: the new drug set to tackle the ‘cancer of psychiatry’September 19, 2024 | ft.comAbbVie (NYSE:ABBV) Expands Eye Care Portfolio with Ripple Therapeutics Collaboration, Boosts Growth PotentialSeptember 18, 2024 | finance.yahoo.com3 High-Dividend Pharma Blue Chips That Are on Sale Right NowSeptember 17, 2024 | stocknews.comQ4 2024 Ceres Global Ag Corp Earnings Call TranscriptSeptember 16, 2024 | gurufocus.comCeres Global Ag Corp (CERGF) Q4 2024 Earnings Call Transcript Highlights: Record Soybean Crush ...September 16, 2024 | gurufocus.com Get Cerevel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERE and its competitors with MarketBeat's FREE daily newsletter. Email Address CERE Media Mentions By Week CERE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CERE News Sentiment▼0.000.64▲Average Medical News Sentiment CERE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CERE Articles This Week▼43▲CERE Articles Average Week Get Cerevel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CNX Resources News Today Warrior Met Coal News Today Arch Resources News Today Hallador Energy News Today Alnylam Pharmaceuticals News Today Teva Pharmaceutical Industries News Today Royalty Pharma News Today BeiGene News Today United Therapeutics News Today Summit Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CERE) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerevel Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerevel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CERE Stock Alerts